Profile data is unavailable for this security.
About the company
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
- Revenue in USD (TTM)1.06m
- Net income in USD-135.28m
- Incorporated2019
- Employees133.00
- LocationMonte Rosa Therapeutics Inc321 Harrison Avenue, Suite 900BOSTON 02118United StatesUSA
- Phone+1 (617) 949-2643
- Fax+1 (302) 655-5049
- Websitehttps://www.monterosatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | 0.00 | -64.12m | 238.37m | 58.00 | -- | 1.62 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Codexis Inc | 74.23m | -65.13m | 238.48m | 174.00 | -- | 3.01 | -- | 3.21 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Metagenomi Inc | 44.76m | -68.26m | 239.02m | 236.00 | -- | -- | -- | 5.34 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 242.74m | 49.00 | -- | 5.46 | -- | 2,996.73 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Century Therapeutics Inc | 1.37m | -133.47m | 247.03m | 152.00 | -- | 1.08 | -- | 180.32 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| AVITA Medical Inc | 50.70m | -44.82m | 247.94m | 207.00 | -- | 7.61 | -- | 4.89 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 250.66m | 133.00 | -- | 1.36 | -- | 235.58 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Sanara Medtech Inc | 68.00m | -4.89m | 256.17m | 107.00 | -- | 5.92 | -- | 3.77 | -0.5873 | -0.5873 | 8.15 | 5.02 | 1.04 | 1.99 | 8.63 | 635,556.60 | -7.68 | -17.73 | -9.30 | -22.07 | 88.80 | 88.08 | -7.39 | -17.13 | 1.02 | -9.21 | 0.184 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| MacroGenics Inc | 43.36m | -23.24m | 256.17m | 339.00 | -- | 2.41 | -- | 5.91 | -0.3754 | -0.3754 | 0.6969 | 1.70 | 0.1465 | 5.13 | 2.00 | 127,896.80 | -7.85 | -37.76 | -9.48 | -45.53 | 84.28 | -- | -53.60 | -133.96 | 3.61 | -96.21 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 260.12m | 158.00 | -- | 0.7577 | -- | 7.79 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Aquestive Therapeutics Inc | 51.50m | -28.77m | 262.19m | 135.00 | -- | -- | -- | 5.09 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 262.48m | 122.00 | -- | 2.51 | -- | 366.04 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 264.11m | 145.00 | -- | 1.59 | -- | 3.62 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
Data as of May 31 2024. Currency figures normalised to Monte Rosa Therapeutics Inc's reporting currency: US Dollar USD
55.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 5.34m | 10.65% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 5.05m | 10.08% |
| Baker Bros. Advisors LPas of 31 Mar 2024 | 4.92m | 9.80% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 4.54m | 9.04% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.87m | 3.74% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.61m | 3.21% |
| Aisling Capital Management LPas of 31 Mar 2024 | 1.47m | 2.94% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 1.41m | 2.81% |
| Citadel Advisors LLCas of 31 Mar 2024 | 980.24k | 1.95% |
| Geode Capital Management LLCas of 31 Mar 2024 | 735.53k | 1.47% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
